Tryptophanyl‐trna synthetase as a potential therapeutic target

23Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Abstract

Tryptophanyl‐tRNA synthetase (WRS) is an essential enzyme that catalyzes the ligation of tryptophan (Trp) to its cognate tRNAtrp during translation via aminoacylation. Interestingly, WRS also plays physiopathological roles in diseases including sepsis, cancer, and autoimmune and brain diseases and has potential as a pharmacological target and therapeutic. However, WRS is still generally regarded simply as an enzyme that produces Trp in polypeptides; therefore, studies of the pharmacological effects, therapeutic targets, and mechanisms of action of WRS are still at an emerging stage. This review summarizes the involvement of WRS in human diseases. We hope that this will encourage further investigation into WRS as a potential target for drug development in various pathological states including infection, tumorigenesis, and autoimmune and brain diseases.

Cite

CITATION STYLE

APA

Ahn, Y. H., Oh, S. C., Zhou, S., & Kim, T. D. (2021, May 1). Tryptophanyl‐trna synthetase as a potential therapeutic target. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms22094523

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free